Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 10, 2011, Pages 1658-1662

  Yoshimasu, Tatsuya ^a   Oura, Shoji ^a   Ohta, Fuminori ^a   Hirai, Yoshimitsu ^a   Naito, Koma ^a   Nakamura, Rie ^a   Nishiguchi, Haruka ^a   Hashimoto, Sayoko ^a   Kawago, Mitsumasa ^a   Okamura, Yoshitaka ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Anticancer drug sensitivity test; EGFR gene; histocytochemistry; mutation; non small cell lung cancer

Indexed keywords

CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; NAVELBINE;

ADULT; AGED; ARTICLE; CANCER INHIBITION; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG RESECTION; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 80053001342     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318221f71a     Document Type: Article

References (24)

1. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-991. (Pubitemid 44343542)
2. Sève P, Lai R, Ding K, et al. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR. 10. Clin Cancer Res 2007;13: 994-999.
3. Reynolds C, Obasaju C, Schell MJ, et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 2009;27:5808-5815.
4. Toyooka S, Takano T, Kosaka T, et al. Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. Cancer Sci 2008;99:303-308. (Pubitemid 351228484)
5. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513-2520. (Pubitemid 47050841)
6. Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-smallcell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010;28:744-752.
7. Kubota T, Sasano N, Abe O, et al. Potential of the histoculture drug response assay to contribute to cancer patient survival. Clin Cancer Res 1995;1:1537-1543. (Pubitemid 26028089)
8. Furukawa T, Kubota T, Hoffman RM. Clinical applications of the histoculture drug response assay. Clin Cancer Res 1995;1:305-311.
9. Ohie S, Udagawa Y, Aoki D, et al. Histoculture drug response assay to monitor chemoresponse. Methods Mol Med 2005;110:79-86.
10. Yoshimasu T, Oura S, Hirai I, et al. Data acquisition for the histoculture drug response assay in lung cancer. J Thorac Cardiovasc Surg 2007; 133:303-308. (Pubitemid 46136244)
11. Mast A, de Arruda M. Invader assay for single-nucleotide polymorphism genotyping and gene copy number evaluation. Methods Mol Biol 2006; 335:173-186.
12. Wu M, Zhao J, Song SW, et al. EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer 2010;67:343-347.
13. Kalikaki A, Koutsopoulos A, Hatzidaki D, et al. Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer 2010;69:110-115.
14. Wu JY, Shih JY, Yang CH, et al. Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer. Int J Cancer 2010;126:247-255.
15. Liu HP, Isaac Wu HD, Chang JW, et al. Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan. J Thorac Oncol 2010;5:1175-1184.
16. Sève P, Isaac S, Trédan O, et al. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005;11:5481-5486.
17. Hirai Y, Yoshimasu T, Oura S, et al. Is class III-tubulin a true predictive marker of sensitivity to vinorelbine in non-small cell lung cancer? Chemosensitivity data evidence. Anticancer Res 2011;31:999-1005.
18. Tanahashi M, Niwa H, Yukiue H, et al. Adjuvant chemotherapy based on the in vitro histoculture drug response assay for non-small cell lung cancer improves survival. J Thorac Oncol 2010;5:1376-1381.
19. Hirai Y, Yoshimasu T, Oura S, et al. Histoculture drug response assay guided adjuvant chemotherapy in patients with ERCC1-positive nonsmall cell lung cancer. [Article in Japanese] Gan To Kagaku Ryoho 2009;36:611-614.
20. Hayashi Y, Kuriyama H, Umezu H, et al. Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer. Intern Med 2009; 48:203-208.
21. Yoshimasu T, Oura S, Hirai I, et al. In vitro evaluation of dose-response curve for paclitaxel in breast cancer. Breast Cancer 2007;14:401-405.
22. Yoshimasu T, Oura S, Hirai I, et al. Dose response curve of paclitaxel measured by histoculture drug response assay. [Article in Japanese] Gan To Kagaku Ryoho 2005;32:497-500.
23. Yoshimasu T, Ohta F, Oura S, et al. Histoculture drug response assay for gefitinib in non-small-cell lung cancer. Gen Thorac Cardiovasc Surg 2009;57:138-143.
24. Takenaka T, Yoshino I, Kouso H, et al. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int J Cancer 2007;121:895-900. (Pubitemid 47106222)